100
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Naldemedine for the Treatment of Opioid-Induced Constipation in Adults with Chronic Noncancer Pain

, & ORCID Icon
Pages 301-306 | Received 15 Apr 2020, Accepted 22 May 2020, Published online: 19 Jun 2020

References

  • Han B , ComptonW , BlancoC. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann. Int. Med.167, 293–201 (2017).
  • Benyamin R , TrescotAM , DattaSet.al Opioid complications and side effects. Pain Physician11(Suppl. 2), S105–S120 (2008).
  • Lacy BE , MearinF , ChangLet.al Bowel disorders. Gastroenterology150(6), 1393–1407 (2016).
  • Stern EK , BrennerDM. Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy. J Pain Res.11, 195–199 (2018).
  • Kalso E , EdwardsJ , MooreR , McQuayH. Opioids in chronic noncancer pain: systematic review of efficacy and safety. Pain112(3), 372–380 (2004).
  • Bell T , PanchalS , MiaskowskiC , BolgeS , MilanovaT , WilliamsonR. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med.10(1), 35–42 (2009).
  • Rauck RL , HongK-SJ , NorthJ. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract.17(3), 329–335 (2017).
  • Nokjov B , BakerJ , MeneesSet.al Is dyssynergic defecation an unrecognized cause of chronic constipation in patients using opioids? Am. J. Gastroenterol.114(11), 1772–1777 (2019).
  • Leppert W . Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des. Devel. Ther.9, 2215–2231 (2015).
  • Hanson B , SiddiqueSM , ScarlettY , SultanS. American Gastroenterological Association Institute technical review on the Medical Management of Opioid-Induced Constipation. Gastroenterology156(1), 229–253 (2019).
  • Crockett SD , GreerKB , HeidelbaughJJ , Falck-YtterY , HansonBJ , SultanS. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology156(1), 218–226 (2019).
  • Brenner DM , HuY , DattoC , CreangaD , CamilleriM. A randomized, multicenter, prospective, crossover, open-label study of factors associated with patient preferences for naloxegol or PEG 3350 for opioid-induced constipation. Am. J. Gastroenterol.114(6), 954–963 (2019).
  • Brenner DM , SternE , CashBD. Opioid-related constipation in patients with noncancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr. Gastroenterol. Rep.19(3), 12 (2017).
  • Chey WD , WebsterL , SostekM , LappalainenJ , BarkerPN , TackJ. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med.370(35), 2387–2396 (2014).
  • Webster L , NagataT , YamadaT , FerreiraJA. A Phase IIa, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic noncancer pain and opioid-induced bowel dysfunction. J. Pain17(4), S94 (2016).
  • Kanemasa T , JoikeK , AraiTet.al Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. Neurogastroenterol. Motil.31(5), e13563 (2019).
  • Blair HA . Naldemedine: a review in opioid-induced constipation. Drugs79(11), 1241–1247 (2019).
  • Webster LR , YamadaT , ArjonaFerreira JC. A Phase IIb, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med.18(12), 2350–2360 (2017).
  • Webster LR , NalamachuS , MorlionBet.al Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled Phase III study. Pain159(5), 987–994 (2018).
  • Hale M , WildJ , ReddyJ , YamadaT , ArjonaFerreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multi-centre, Phase III, double-blind, randomized, parallel-group trials. Lancet Gastroenterol. Hepatol.2(8), 555–564 (2017).
  • Nee J , ZakariM , SugarmanMAet.al Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol.16(10), 1569–1584 (2018).
  • Luthra P , BurrNE , BrennerDM , FordAC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut68(3), 434–444 (2019).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.